Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Ranibizumab Market Size, Value And Growth Trends Through 2030
The ranibizumab market has experienced consistent expansion over recent years, with projections indicating an increase from $2.76 billion in 2025 to $2.87 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.0%. This historic period of growth has been driven by several factors, including a rising prevalence of age-related macular degeneration, the confirmed clinical effectiveness of anti-VEGF therapy, an increasing occurrence of diabetic retinopathy, enhanced diagnostic imaging capabilities for retinal conditions, and early regulatory clearances granted for ranibizumab.
The ranibizumab market is forecasted to experience consistent expansion over the coming years, reaching a valuation of $3.31 billion by 2030, driven by a compound annual growth rate (CAGR) of 3.6%. This anticipated growth is supported by several factors in the forecast period, including the global increase in the elderly population, a rising worldwide incidence of diabetes, broader availability of sophisticated ophthalmic treatments, growing uptake of intravitreal injections, and continuous enhancements in retinal disease screening programs. Key trends shaping this period consist of a growing preference for anti-VEGF therapies to manage retinal conditions, an increased inclination toward prefilled syringe formats, heightened treatment needs for diabetic eye diseases, the proliferation of specialized ophthalmology clinics, and a greater reliance on long-term maintenance therapy for chronic retinal disorders.
Download A Free Sample Report For Comprehensive Market Insights:
Ranibizumab Market Growth Factors Supporting Long-Term Expansion
The rising occurrence of eye-related disorders is anticipated to fuel the expansion of the ranibizumab market in the coming years. Eye diseases include various conditions that affect the eyes, often leading to compromised vision or overall ocular health. This growing trend in eye diseases is driven by factors like an aging populace, evolving lifestyles, and a higher incidence of chronic ailments such as diabetes. Ranibizumab is employed in treating disorders like age-related macular degeneration and diabetic retinopathy, mitigating vision loss amid this escalation in eye diseases. For example, in August 2023, the World Health Organization (WHO), an intergovernmental body based in Switzerland, reported that around 2.2 billion individuals worldwide suffer from near or distance vision impairment. Consequently, the growing frequency of eye diseases is set to boost the ranibizumab market’s growth.
Ranibizumab Market Segment Outlook: Which Categories Are Expanding The Fastest?
The ranibizumab market covered in this report is segmented –
1) By Product: Single Use Prefilled Syringe, Single Use Glass Vial
2) By Application: Wet Age Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Myopic Choroidal Neovascularization (MCNV), Retinal Vein Occlusion (RVO)
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Single Use Prefilled Syringe: 0.3 Ml Syringe, 0.5 Ml Syringe, 1 Ml Syringe, Other Volume Variants
2) By Single Use Glass Vial: 0.5 Mg Or 0.05 Ml Vial, 1.0 Mg Or 0.1 Ml Vial, 2.0 Mg Or 0.2 Ml Vial, Other Volume Variants
Ranibizumab Market Industry Trends Shaping Future Revenue Growth
Leading players in the ranibizumab sector are increasingly prioritizing affordable therapeutic options, particularly biosimilars of ranibizumab, designed to combat vision loss in individuals with retinal conditions. A ranibizumab biosimilar is a biologic agent that closely mirrors the original medication but is sold under a distinct brand name, delivering a cheaper substitute while preserving comparable effectiveness and safety standards. As an example, in April 2024, Formycon AG, a biotechnology firm headquartered in Germany, and Bioeq AG, a biopharmaceutical company based in Switzerland, introduced the commercial availability of FYB201, a Lucentis (ranibizumab) biosimilar, across Canada and Switzerland. This rollout follows regulatory approvals from Health Canada, which authorized it as Ranopto, and Swissmedic, which approved it under the name Ranivisio. FYB201 provides a novel, high-quality, effective, and budget-friendly treatment option for individuals dealing with severe retinal disorders. It has already proven its worth as an economical remedy for patients in the USA and multiple European regions.
Ranibizumab Market Key Companies And Competitive Benchmarking
Major companies operating in the ranibizumab market are F. Hoffmann-La Roche AG, Genentech Inc., Bayer AG, Novartis AG, Biocon Limited, Samsung Biologics Co Ltd, Celltrion Healthcare Co Ltd, Formycon AG, Coherus BioSciences Inc, Xbrane Biopharma AB, Alvotech, Stada Arzneimittel AG, Sun Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Ltd, Enzene Biosciences Ltd, Amman Pharmaceutical Industries
Access The Complete Ranibizumab Market Report:
Ranibizumab Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the ranibizumab market in 2025. The regions covered in the ranibizumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model